Novel syngeneic model of anti-mouse CLDN18.2 CAR -T therapy for gastric cancer demonstrates a synergy with TGF-β and PD-L1 inhibitors

一种新型的抗小鼠CLDN18.2 CAR-T疗法同源模型在胃癌治疗中显示出与TGF-β和PD-L1抑制剂的协同作用

阅读:3
作者:Min-Jung Seo,Jin Hue Jeong,Han Na Park,In-Pyo Baek,Jun Won Park,Seo Young Kim,Yu Ri Choi,Seulki Choi,Seung Min Ham,Dongmin Park,Hye-Ran Kim,Ho Kyung Seo,Hark Kyun Kim

Abstract

There are very few syngeneic mouse cell line models available for gastric cancer owing to the rarity of stomach epithelium-specific promoter. Mouse cell line models are useful to study an immunologically intact tumor microenvironment, especially in the setting of CAR-T studies that often use immunocompromised mice. To establish a mouse cell line faithfully recapitulating human gastric cancer, we generated the S6M cell line from an autochthonous gastric cancer formed in the stomach of a female mouse deficient in Smad4, Trp53, and Cdh1 (Pdx-1-Cre; Smad4 F/F ; Trp53 F/F ; Cdh1 F/+ ). S6M readily formed a tumor when injected into syngeneic mice and demonstrated histologic and molecular features consistent with human intestinal gastric adenocarcinoma. Notably, S6M overexpressed the isoform 2 of claudin 18 (CLDN18.2), an important molecular therapeutic target in human gastric adenocarcinomas. Anti-mouse CLDN18.2 CAR-T cells suppressed tumor growth of mice bearing the syngeneic graft of S6M but not the CLDN18.2-low S1M cell line. Dual inhibition of immunosuppressive molecules TGF-β and PD-L1 enhanced the in vivo efficacy of anti-mouse CLDN18.2 CAR-T against S6M cells by recruiting NK cells to tumor microenvironment, suggesting the potential utility of our novel syngeneic gastric cancer cell line model in designing innovative clinical therapeutic approaches.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。